Company
Since 1909, Grifols has worked to improve the health and well-being of people around the world.
Corporate Structure
Innovation
Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.
Sustainability
Grifols' longstanding commitment to people and the planet entails helping society on all fronts.
Social Commitment
Investors
Stock Information
Financials
Communications with CNMV and SEC
Corporate Governance
Careers
People are at the heart of our business. We are committed to continued investment in training and development.
Media
Latest news about the company and contact information for journalists and communication professionals.
Suppliers
At Grifols, we believe in long-term, mutually trusting relationships with our partners.
Connect with us
Showing 573 search results
Grifols reorganizes its operating model to accelerate execution of its strategic roadmap
Grifols doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency
Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2025
Grifols announces a next-generation automated system to enhance efficiency and flexibility in transfusion medicine laboratories
Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting
Grifols launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols Egypt continues its growth plan through 2029 with an additional investment of €180 million
Grifols breaks ground on new manufacturing site in Spain
Grifols collaborates with CRAM on a project to bring marine conservation closer to hospitalized children
Grifols doubles the number of positions in its vocational training program over the past year in Spain
Grifols increases Q1 2026 revenues by 3.3% to €1.7billion, and net profit 21.9% to €73 million
Grifols strengthens its position among the world’s most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score